Maximizing value from off patent drugs key to pandemic recovery, trade group says

As countries shift to investment in healthcare system recovery and ongoing management of COVID-19, off-patent medicines will be critical to their success, according to Medicines for Europe.

The trade group, which represents Europe’s generics and biosimilars industries, has stressed the necessity for these medicines to become the focal point of pharmaceutical policies.

"This is also an important moment for regulatory harmonization and reliance, embracing the digital agenda in healthcare and developing smart health and trade policies"Rebecca Guntern, who is the group’s interim president, spoke about the topic at the Medicines for Europe and International Generic and Biosimilar Medicines Association (IGBA) Annual Conference.